Kokilaben Dhirubhai Ambani Hospital, Mumbai, has launched OncoKH 500 PLUS, in-house genomic profiling test that screens over 500 cancer-related genes in a single run.
OncoKH 500 PLUS enables oncologists to make more accurate, faster, and individualised treatment decisions by identifying driver mutations, gene fusions, and copy number variations (CNVs), tumor mutational burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), and other clinically significant biomarkers.
Dr Santosh Shetty, Executive Director & CEO, Kokilaben Dhirubhai Ambani Hospital said, “At Kokilaben Hospital, we have built an ecosystem that mirrors the best global standards in oncology combining cutting-edge technology, highly trained multidisciplinary teams, and a patient-first approach. With the launch of OncoKH 500 PLUS, we are taking precision oncology a step further by ensuring that every cancer patient has access to genetic insights that can truly transform their treatment outcomes. This is not just a test, it is a gateway to world-class, personalised cancer care delivered right here in India.”
OncoKH 500 PLUS gives a single, high-accuracy report from just one biopsy eliminating the need for multiple rounds of testing or sending samples to third-party labs. It covers 500+ genes, including SNVs, indels, fusions, CNVs, MSI, TMB, and HRD
Dr Amrit Kaur Kaler, Consultant-Molecular Pathology, Kokilaben Dhirubhai Ambani Hospital added, “Every cancer behaves differently, and many patients do not respond to standard chemotherapy due to hidden resistance mutations. This test allows us to decode the tumor’s entire genetic makeup from actionable mutations to resistance markers so we can personalise treatment from day one. In the first month itself, we have seen remarkable results and a strong response from both Indian and international patients.”